Developer docs
API playgroundTry for free, no card

Search company profiles

Olainfarm

Full company profile

uuid003fmyi

Namestring
Olainfarm
Legal namestring
Akciju sabiedrība "Olpha"
Websiteurl
olainfarm.lv
Company typeenum
Public
Founded yearint
1972
Descriptiontext

Olainfarm, now operating under the Olpha brand, is a publicly listed Latvian pharmaceutical manufacturer headquartered in Olaine. Founded in 1972, the company employs 850+ specialists and operates through five group companies. It produces finished drug forms, active pharmaceutical substances (APIs), and intermediates, with a portfolio of more than 60 drug forms, 25 active pharmaceutical substances, and more than 20 intermediates spanning ten therapeutic areas: urology, hematology, cardiology, allergology, neurology, oncology, pain and inflammation, anesthesiology, anti-infectives, gastroenterology, endocrinology, and pulmonology.

The company distributes finished products through direct pharmaceutical channels in more than 60 markets across the Baltic States, Eastern Europe, Central Asia, the Caucasus, the Balkans, and Mongolia. Alongside its captive product portfolio, Olpha runs a portfolio of business-to-business services including pharmaceutical contract manufacturing, pharmaceutical co-development, pharmaceutical out-licensing, dietary supplement manufacturing, and product lifecycle management, targeting pharmaceutical companies as partners. It also operates research and development functions for both APIs/intermediates and finished dosage forms, including product development and registration support.

The firm is listed on the Nasdaq Riga stock exchange under the ticker OLF (legal name AS Olpha). Recent strategic activity includes a 5.84 million EUR investment to expand production capacity at the Olaine site, an announced pivot into drug development services exports, and a 2024 corporate rebranding from Olainfarm to Olpha. The management board is chaired by Valerijs Maligins, with functional directors leading manufacturing, quality management, technical, product development, and administration. Historical M&A activity between 2011 and 2016 added pharmacy, diagnostics (Klinika DiaMed), medical devices (Tonus Elast), and cosmetics (Kiwi Cosmetics) assets to the group.

Short descriptiontext

Olpha (formerly Olainfarm) is a Latvian pharmaceutical manufacturer producing finished drug forms, active pharmaceutical ingredients, and intermediates across ten therapeutic areas, serving 60+ markets through 850+ specialists and a portfolio of B2B services including contract manufacturing and licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersOlaine, Latvia
HQ citystring
Olaine
HQ countrystring
Latvia
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, finished dosage forms, active pharmaceutical ingredients, contract manufacturing, drug formulation
Industry2 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Pharmaceutical Manufacturing and Sales
TypeOne Time License
Description

Manufacturing and sale of pharmaceutical products including finished dosage forms, active pharmaceutical ingredients, and intermediates across 10 therapeutic areas

olpha.eu
2Contract Manufacturing
TypeProfessional Services
Description

Custom manufacturing services for pharmaceutical partners, producing finished dosage forms, APIs, and intermediates

olpha.eu
3Pharmaceutical Co-development
TypeLicensing Royalties
Description

Joint development partnerships for pharmaceutical products and formulations

olpha.eu
4Pharmaceutical Licensing
TypeLicensing Royalties
Description

Licensing arrangements for pharmaceutical products and formulations

olpha.eu
5Nutritional Supplement Manufacturing
TypeHardware Sales
Description

Production of dietary supplements for business partners

olpha.eu
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Olainfarm (brand: Olpha) manufactures and sells finished pharmaceutical dosage forms, active pharmaceutical ingredients (APIs), and intermediates across 10 therapeutic areas. In addition to its branded pharmaceutical portfolio of 60+ drug forms, the company offers contract manufacturing, pharmaceutical co-development, pharmaceutical licensing, and dietary supplement manufacturing services to business partners across 60+ markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Olpha (formerly Olainfarm) is a leading pharmaceutical manufacturer in the Baltic region with more than 50 years of experience. The company offers a unified portfolio of over 60 drug forms, 25 active pharmaceutical substances, and 20+ intermediates across 10 therapeutic groups (Urology, Hematology, Cardiology, Allergology, Neurology, Oncology, Pain & Inflammation, Anesthesiology, Anti-infectives, Gastroenterology, Endocrinology, Pulmonology). Beyond its core pharmaceutical products, Olpha provides comprehensive business services including contract manufacturing, pharmaceutical co-development, pharmaceutical licensing, dietary supplement manufacturing, and product management. The company operates with over 850 specialists and serves 60+ markets through 5 group companies.

Product and service8 records
1Pharmaceutical Products Portfolio
CategoryPharmaceutical Manufacturing
Description

Olpha's core pharmaceutical product portfolio comprising more than 60 drug forms, 25 active pharmaceutical substances, and more than 20 intermediates for family health. Products cover 10 therapeutic groups including Urology, Hematology, Cardiology, Allergology, Neurology, Oncology, Pain & Inflammation, Anesthesiology, Anti-infectives, Gastroenterology, Endocrinology, and Pulmonology.

2Contract Manufacturing
CategoryContract Manufacturing Services
Description

Pharmaceutical contract manufacturing services for finished drug forms, active pharmaceutical substances, and intermediates, leveraging over 850 specialists and more than 50 years of experience. Designed for pharmaceutical business partners seeking reliable manufacturing partners.

3Pharmaceutical Co-development
CategoryPharmaceutical Development Services
Description

Collaborative pharmaceutical development services for new drug formulations and products, enabling joint development partnerships with pharmaceutical companies.

4Pharmaceutical Licensing
CategoryLicensing Services
Description

Out-licensing services for pharmaceutical products to enable market expansion for business partners across multiple geographies.

5Dietary Supplement Manufacturing
CategoryContract Manufacturing Services
Description

Manufacturing services for nutritional and dietary supplements for business partners.

6Product Management
CategoryProduct Management Services
Description

Comprehensive product lifecycle management services for pharmaceutical products offered to business partners.

7Active Pharmaceutical Substances and Intermediates R&D
CategoryPharmaceutical R&D Services
Description

Research and development services for active pharmaceutical substances and intermediates offered to business partners.

8Finished Drug Form R&D
CategoryPharmaceutical R&D Services
Description

Research and development services for finished dosage forms offered to business partners.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest Polish pharmaceutical manufacturers producing generics, APIs, and finished dosage forms. Comparable scale, vertical integration across the value chain, and focus on Central and Eastern European markets with growing international distribution.

TypeDirect peer
Description

Hungarian-headquartered pharmaceutical company with strong generics, APIs, and branded pharma operations across CEE and CIS regions. Comparable vertical integration (APIs through finished forms), regional geographic footprint, and established presence in markets Olpha serves.

TypeDirect peer
Description

Latvian-headquartered pharmaceutical manufacturer producing finished dosage forms, APIs, and generics across multiple therapeutic areas. Closest comparable peer given shared Latvian/Baltic origin, similar vertical integration profile, and overlapping generic pharma business model.

TypeRegional player
Description

Ukrainian pharmaceutical manufacturer producing generics and finished dosage forms primarily for the Ukrainian and CIS markets. Comparable vertical integration and therapeutic breadth, but focused on a different (CIS-centric) geography than Olpha's broader multi-market presence.

TypeBroad incumbent
Description

World's largest generic pharmaceutical manufacturer with massive global API and finished dose capacity. Competes with Olpha in generic categories across all therapeutic areas and in the same Eastern European markets, but at substantially larger scale and broader portfolio scope.

6Balkan Pharmaceuticals
TypeRegional player
Description

Moldovan-based pharmaceutical manufacturer producing generics, APIs, and finished dosage forms for Eastern European and CIS markets. Comparable product category and manufacturing scope, with regional focus on similar territories to Olpha's CIS distribution.

7Sandoz (Novartis)
TypeBroad incumbent
Description

Global generics-focused division of Novartis, one of the largest generic and biosimilar manufacturers worldwide. Competes across Olpha's therapeutic categories and geographies, with substantially greater scale, R&D budget, and regulatory footprint.

TypeDirect peer
Description

Slovenian generic pharmaceutical manufacturer with vertically integrated API and finished dose production across Central and Eastern European markets. Highly comparable business model, geographic focus on CEE/CIS, and generic product portfolio spanning similar therapeutic categories.

TypeDirect peer
Description

German-based European generics and consumer healthcare company with extensive generic pharmaceutical portfolio and strong presence in CEE/CIS markets. Comparable multi-market distribution model and generic finished dosage form focus.

TypeDirect peer
Description

European generics-focused pharmaceutical manufacturer headquartered in Prague, serving CEE and Western European markets with a broad generic and OTC portfolio. Comparable product portfolio breadth, therapeutic diversification, and B2B partnership offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Olainfarm

Pharmaceutical Manufacturingolainfarm.lv

Olpha (formerly Olainfarm) is a Latvian pharmaceutical manufacturer producing finished drug forms, active pharmaceutical ingredients, and intermediates across ten therapeutic areas, serving 60+ markets through 850+ specialists and a portfolio of B2B services including contract manufacturing and licensing.

What Olainfarm does

Olainfarm, now operating under the Olpha brand, is a publicly listed Latvian pharmaceutical manufacturer headquartered in Olaine. Founded in 1972, the company employs 850+ specialists and operates through five group companies. It produces finished drug forms, active pharmaceutical substances (APIs), and intermediates, with a portfolio of more than 60 drug forms, 25 active pharmaceutical substances, and more than 20 intermediates spanning ten therapeutic areas: urology, hematology, cardiology, allergology, neurology, oncology, pain and inflammation, anesthesiology, anti-infectives, gastroenterology, endocrinology, and pulmonology.

The company distributes finished products through direct pharmaceutical channels in more than 60 markets across the Baltic States, Eastern Europe, Central Asia, the Caucasus, the Balkans, and Mongolia. Alongside its captive product portfolio, Olpha runs a portfolio of business-to-business services including pharmaceutical contract manufacturing, pharmaceutical co-development, pharmaceutical out-licensing, dietary supplement manufacturing, and product lifecycle management, targeting pharmaceutical companies as partners. It also operates research and development functions for both APIs/intermediates and finished dosage forms, including product development and registration support.

The firm is listed on the Nasdaq Riga stock exchange under the ticker OLF (legal name AS Olpha). Recent strategic activity includes a 5.84 million EUR investment to expand production capacity at the Olaine site, an announced pivot into drug development services exports, and a 2024 corporate rebranding from Olainfarm to Olpha. The management board is chaired by Valerijs Maligins, with functional directors leading manufacturing, quality management, technical, product development, and administration. Historical M&A activity between 2011 and 2016 added pharmacy, diagnostics (Klinika DiaMed), medical devices (Tonus Elast), and cosmetics (Kiwi Cosmetics) assets to the group.

Olainfarm firmographics

Firmographics
Name
Olainfarm
Legal name
Akciju sabiedrība "Olpha"
Website
https://olainfarm.lv
Company type
Public
Founded year
1972
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Olpha (formerly Olainfarm) is a Latvian pharmaceutical manufacturer producing finished drug forms, active pharmaceutical ingredients, and intermediates across ten therapeutic areas, serving 60+ markets through 850+ specialists and a portfolio of B2B services including contract manufacturing and licensing.
Ownership category
akta.pro rank

Olainfarm industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions

Keywords

  • Pharmaceutical manufacturing
  • Finished dosage forms
  • Active pharmaceutical ingredients
  • Contract manufacturing
  • Drug formulation

Where Olainfarm is headquartered

Location

Headquarters

HQ city
Olaine
HQ country
Latvia
HQ region
Europe

Offices1 record

Markets served

Olainfarm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical Manufacturing and Sales: Manufacturing and sale of pharmaceutical products including finished dosage forms, active pharmaceutical ingredients, and intermediates across 10 therapeutic areas
  2. Contract Manufacturing: Custom manufacturing services for pharmaceutical partners, producing finished dosage forms, APIs, and intermediates
  3. Pharmaceutical Co-development: Joint development partnerships for pharmaceutical products and formulations
  4. Pharmaceutical Licensing: Licensing arrangements for pharmaceutical products and formulations
  5. Nutritional Supplement Manufacturing: Production of dietary supplements for business partners

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Olainfarm product offering

Product offering

Core offering

Olainfarm (brand: Olpha) manufactures and sells finished pharmaceutical dosage forms, active pharmaceutical ingredients (APIs), and intermediates across 10 therapeutic areas. In addition to its branded pharmaceutical portfolio of 60+ drug forms, the company offers contract manufacturing, pharmaceutical co-development, pharmaceutical licensing, and dietary supplement manufacturing services to business partners across 60+ markets.

Product overview

Olpha (formerly Olainfarm) is a leading pharmaceutical manufacturer in the Baltic region with more than 50 years of experience. The company offers a unified portfolio of over 60 drug forms, 25 active pharmaceutical substances, and 20+ intermediates across 10 therapeutic groups (Urology, Hematology, Cardiology, Allergology, Neurology, Oncology, Pain & Inflammation, Anesthesiology, Anti-infectives, Gastroenterology, Endocrinology, Pulmonology). Beyond its core pharmaceutical products, Olpha provides comprehensive business services including contract manufacturing, pharmaceutical co-development, pharmaceutical licensing, dietary supplement manufacturing, and product management. The company operates with over 850 specialists and serves 60+ markets through 5 group companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Products Portfolio Olpha's core pharmaceutical product portfolio comprising more than 60 drug forms, 25 active pharmaceutical substances, and more than 20 intermediates for family health. Products cover 10 therapeutic groups including Urology, Hematology, Cardiology, Allergology, Neurology, Oncology, Pain & Inflammation, Anesthesiology, Anti-infectives, Gastroenterology, Endocrinology, and Pulmonology.
  • Contract Manufacturing Pharmaceutical contract manufacturing services for finished drug forms, active pharmaceutical substances, and intermediates, leveraging over 850 specialists and more than 50 years of experience. Designed for pharmaceutical business partners seeking reliable manufacturing partners.
  • Pharmaceutical Co-development Collaborative pharmaceutical development services for new drug formulations and products, enabling joint development partnerships with pharmaceutical companies.
  • Pharmaceutical Licensing Out-licensing services for pharmaceutical products to enable market expansion for business partners across multiple geographies.
  • Dietary Supplement Manufacturing Manufacturing services for nutritional and dietary supplements for business partners.
  • Product Management Comprehensive product lifecycle management services for pharmaceutical products offered to business partners.
  • Active Pharmaceutical Substances and Intermediates R&D Research and development services for active pharmaceutical substances and intermediates offered to business partners.
  • Finished Drug Form R&D Research and development services for finished dosage forms offered to business partners.

Companies that use Olainfarm

Customer profile

Segments3 records

Ideal customer profiles3 records

Olainfarm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Olainfarm partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Olainfarm competitors and assessment

Company assessment

Direct peers

  • Polpharma: One of the largest Polish pharmaceutical manufacturers producing generics, APIs, and finished dosage forms. Comparable scale, vertical integration across the value chain, and focus on Central and Eastern European markets with growing international distribution.
  • Gedeon Richter: Hungarian-headquartered pharmaceutical company with strong generics, APIs, and branded pharma operations across CEE and CIS regions. Comparable vertical integration (APIs through finished forms), regional geographic footprint, and established presence in markets Olpha serves.
  • Grindeks: Latvian-headquartered pharmaceutical manufacturer producing finished dosage forms, APIs, and generics across multiple therapeutic areas. Closest comparable peer given shared Latvian/Baltic origin, similar vertical integration profile, and overlapping generic pharma business model.
  • KRKA: Slovenian generic pharmaceutical manufacturer with vertically integrated API and finished dose production across Central and Eastern European markets. Highly comparable business model, geographic focus on CEE/CIS, and generic product portfolio spanning similar therapeutic categories.
  • STADA Arzneimittel: German-based European generics and consumer healthcare company with extensive generic pharmaceutical portfolio and strong presence in CEE/CIS markets. Comparable multi-market distribution model and generic finished dosage form focus.
  • Zentiva: European generics-focused pharmaceutical manufacturer headquartered in Prague, serving CEE and Western European markets with a broad generic and OTC portfolio. Comparable product portfolio breadth, therapeutic diversification, and B2B partnership offerings.

Regional players

  • Darnitsa: Ukrainian pharmaceutical manufacturer producing generics and finished dosage forms primarily for the Ukrainian and CIS markets. Comparable vertical integration and therapeutic breadth, but focused on a different (CIS-centric) geography than Olpha's broader multi-market presence.
  • Balkan Pharmaceuticals: Moldovan-based pharmaceutical manufacturer producing generics, APIs, and finished dosage forms for Eastern European and CIS markets. Comparable product category and manufacturing scope, with regional focus on similar territories to Olpha's CIS distribution.

Broad incumbents

  • Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with massive global API and finished dose capacity. Competes with Olpha in generic categories across all therapeutic areas and in the same Eastern European markets, but at substantially larger scale and broader portfolio scope.
  • Sandoz (Novartis): Global generics-focused division of Novartis, one of the largest generic and biosimilar manufacturers worldwide. Competes across Olpha's therapeutic categories and geographies, with substantially greater scale, R&D budget, and regulatory footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Olainfarm social profiles

Digital presence

Olainfarm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Olainfarm leadership team

Management profile

Number of profiles

Profiles6 records

Olainfarm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Olainfarm M&A and investment

M&A and investment

M&A4 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Olainfarm

What does Olainfarm do?

Olainfarm (brand: Olpha) manufactures and sells finished pharmaceutical dosage forms, active pharmaceutical ingredients (APIs), and intermediates across 10 therapeutic areas. In addition to its branded pharmaceutical portfolio of 60+ drug forms, the company offers contract manufacturing, pharmaceutical co-development, pharmaceutical licensing, and dietary supplement manufacturing services to business partners across 60+ markets.

Is Olainfarm a public or private company?

Olainfarm is a public company. It is classified as public and is currently operating.

When was Olainfarm founded?

Olainfarm was founded in 1972. It employs 1,001 to 5,000 people.

Where is Olainfarm based?

Olainfarm is headquartered in Olaine, Latvia, in the Europe region.

How does Olainfarm make money?

Five revenue lines are on record. Pharmaceutical Manufacturing and Sales are the primary driver. The others are contract Manufacturing, pharmaceutical Co-development, pharmaceutical Licensing and nutritional Supplement Manufacturing.

Who are Olainfarm's main competitors?

Direct peers on record are Polpharma, Gedeon Richter, Grindeks, KRKA, STADA Arzneimittel and Zentiva. Regional players are Darnitsa and Balkan Pharmaceuticals. Broad incumbents are Teva Pharmaceutical Industries and Sandoz (Novartis).

Does Olainfarm have an API?

No public API is recorded for Olainfarm.

What industry is Olainfarm in?

Olainfarm's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireRegarding results of a share buy-back offerOn December 13, 2021, AS AB CITY submitted results of a share buy-back offer to Olainfarm. The offer sold 383,076 shares, leaving AB CITY with 3,752,305 shares, representing 96.12% of total voting rights.GlobeNewswireInformation about the end of mandatory offer of share repurchaseOlainfarm announced that its mandatory share repurchase offer will end on December 7, 2021 at 16:00. The repurchase price is EUR 9.26 per share. No further details were provided.GlobeNewswireComment on the interview for the journal Dienas BiznessOlainfarm's management board rejected Roberts Tavjevs' interview claim that no dividends will be paid for five years, citing a contrary dividend policy. The board noted only the shareholders' meeting can decide dividend amounts, and any policy changes require council approval.GlobeNewswireDECISIONS of the extraordinary meeting of shareholders of joint stock company “Olainfarm” held on October 14th, 2021Olainfarm's extraordinary shareholder meeting on October 14, 2021 elected BDO Assurance as auditor for 2021, approved amendments to its articles of association, and brought actions against former supervisory council and management board members. The meeting also decided to exclude shares from the regulated market.GlobeNewswireImportant information about the procedure of the extraordinary shareholders’ meeting of joint stock company “Olainfarm”Olainfarm's management board invited shareholders to an extraordinary meeting on 14 October 2021, to be held electronically under COVID-19 regulations. Shareholders applying by 14 October 2021 by 9:30 will receive access information via email.GlobeNewswireAgenda and draft decisions of the extraordinary shareholders' meeting of joint stock company “Olainfarm”Olainfarm's management board convened an extraordinary shareholders' meeting on 14 October 2021, with an agenda including auditor election, articles of association amendments, and legal actions against former supervisory and management board members. The meeting also proposed excluding shares from the regulated market, with a warning of potential mandatory share repurchase obligations.GlobeNewswireNotification on convocation of the Joint Stock Company “Olainfarm” Extraordinary General Meeting of ShareholdersOlainfarm's management board announced an extraordinary shareholders meeting on October 14, 2021, to be held electronically via Microsoft Teams. The agenda includes electing a certified auditor for the 2021 annual report and setting their remuneration. Shareholders may vote in advance or participate remotely.GlobeNewswireIn H1 2021 Olainfarm Group continues stable growthOlainfarm Group reported H1 2021 sales of EUR 66,671k, down slightly from the prior year, with net profit falling 23% to EUR 7,668k. Gross profit margin dropped to 58.0% from 61.5%, and EBITDA margin to 18.2%. The company paid a dividend of EUR 2,394k and plans Phase 3 trials and a new urology product launch.GlobeNewswireRegarding results of a share buy-back offerOn August 18, 2021, AS AB CITY submitted a report to Olainfarm on the results of a share buy-back offer. The offer covered 2,427,408 shares, representing 17.23% of voting rights, with indirect holdings totaling 48.08%.GlobeNewswireImportant information about Extraordinary General meeting of shareholders of June 18, 2021Olainfarm's management board announced its Extraordinary General Meeting of shareholders for June 18, 2021, will be held remotely via Microsoft Teams due to COVID-19 restrictions. Shareholders must submit completed application forms by June 16, 2021, and voting will be conducted electronically. The board reserves the right to change the procedure if epidemiological conditions change.